Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Ambreesh Chawla

Rheumatology Cleveland, OH Medical Doctor

NPI 1669868907 CMS profile 8343185

9500 Euclid Ave, Cleveland, OH 44195

Open in the dashboard

General payments

$1,071

46 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ambreesh Chawla of Cleveland, OH is reported in the CMS Open Payments database as having received $1,071 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28 1
2024 General $110 1
2022 General $187 2
2021 General $280 16
2020 General $467 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ambreesh Chawla
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Ambreesh Chawla were reported at $28. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Ambreesh Chawla Rheumatology median Middle half National median
2019 $0 $744 $153–$2,687 $163
2020 $467 $462 $98–$2,027 $114
2021 $280 $531 $101–$2,153 $132
2022 $187 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $110 $830 $166–$2,660 $164
2025 $28 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Amgen Inc. $304 17 payments
  2. UCB, Inc. $132 4 payments
  3. Lilly USA, LLC $118 6 payments
  4. AstraZeneca Pharmaceuticals LP $110 1 payment
  5. AbbVie, Inc. $107 6 payments
  6. Janssen Scientific Affairs, LLC $99 1 payment
  7. E.R. Squibb & Sons, L.L.C. $38 2 payments
  8. Pfizer Inc. $31 2 payments
  9. Acumed LLC $28 1 payment
  10. Radius Health, Inc. $26 2 payments
  11. Other $80 4 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $958 43 payments
  2. Education $113 3 payments
Products named General payments · program years 2020–2025
  1. Cimzia $132 4 payments
  2. SIMPONI ARIA $117 2 payments
  3. STELARA $117 2 payments
  4. TREMFYA $99 1 payment
  5. Enbrel Inflammation $94 8 payments
  6. TALTZ $91 4 payments
  7. Prolia $87 6 payments
  8. OLUMIANT $67 3 payments
  9. Enbrel Inflammation $54 3 payments
  10. OFEV $46 2 payments
  11. Other $468 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,393

Median for Rheumatology: 1,511

Drug cost

$683,836

Median for Rheumatology: $1,139,948

Branded share of claims

18.8%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 27 $197,658
Humira(Cf) Pen Adalimumab Brand 27 $197,528
Actemra Actpen Tocilizumab Brand 24 $115,769
Humira Pen Adalimumab Brand 14 $93,436
Forteo Teriparatide Brand 12 $51,460
Hydroxychloroquine Sulfate Generic 314 $7,736
Mycophenolate Mofetil Generic 12 $4,287
Methotrexate Methotrexate Sodium Brand 158 $3,208
Leflunomide Generic 49 $2,057
Colchicine Generic 50 $1,832

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$38,503

Medicare's payments for the services billed

Medicare patients

247

Average age 73

Services billed

679

180 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Osteoporosis 39%
Depression 27%
Chronic kidney disease 25%
Ischemic heart disease 24%
Diabetes 22%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record